These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 22897728)

  • 1. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.
    Xu XJ; Zhao HZ; Tang YM
    Leuk Lymphoma; 2013 Feb; 54(2):255-60. PubMed ID: 22897728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types.
    Montagna E; de Campos NSP; Porto VA; da Silva GCP; Suarez ER
    BMC Cancer; 2024 Aug; 24(1):1037. PubMed ID: 39174908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
    Oh I; Oh Y; Ohmine K
    Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
    Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
    BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.
    Hao L; Li T; Chang LJ; Chen X
    Curr Med Chem; 2019; 26(17):3068-3079. PubMed ID: 28762313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies.
    Tam CS
    Leuk Lymphoma; 2013 Feb; 54(2):215-6. PubMed ID: 22950939
    [No Abstract]   [Full Text] [Related]  

  • 13. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
    Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
    Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
    Oluwole OO; Davila ML
    J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA
    Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates on CAR T-cell therapy in B-cell malignancies.
    Jacoby E; Shahani SA; Shah NN
    Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.